Social Capital Suvretta Holdings Corp. III (NASDAQ:DNAC) announced in an 8-K this morning that it intends to adjourn its 10 am ET special meeting to complete its combination with drug developer ProKidney and reconvene on a later unspecified date.
The reason given was that the parties needed additional time to satisfy “conditions to closing of the Business Combination with respect to approval by The Nasdaq Capital Market of a listing application” for the combined company’s shares.
Interestingly, there is a minimum cash closing condition of $500 million, but this is backstopped by a fully committed PIPE of $575 million at $10 per share. The PIPE is led by a $125 million contribution from Social Capital, with an additional $50 million from ProKidney’s existing investors, approximately $30 million from Suvretta Capital’s Averill strategy with the remaining $370 million coming from institutional investors and family offices.
Social Capital Suvretta III shares dropped -14.7% to a close at $8.41 yesterday after the SPAC passed its initial redemption deadline, but it is currently up about 7% in the pre-market.
The parties initially announced their $1.8 billion combination on January 18. Winston-Salem, North Carolina-based ProKidney has launched Phase III trials of its REACT cellular therapy which promises to slow the progression of chronic kidney disease (CKD) and potentially regenerate tissues and function.
Many things go into an M&A transaction negotiation, but one of the most common points at issue in SPAC deals is the fate of the sponsor’s promote. While the two sides might wrangle back and forth on the target’s valuation and potential earnout consideration, it is also common for the sponsor to agree to concessions...
At the SPAC of Dawn The tantalizing “will they, won’t they” drama around rate cuts appears set to finally come to a head this week as the Federal Reserve is expected to make an interest rate decision Wednesday morning. But, that is far from all that is going down in SPACland this week. The five...
Terms Tracker for the Week Ending September 13, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We were expecting this week to be busier than it was since it was the first 5-day week post-Summer. However, it was actually very light....
Alpha Star (NASDAQ:ALSA) has entered into a definitive agreement to combine with fintech firm XDATA at an equity value of $180 million. Tallinn, Estonia-based XData provides payment software and digital banking systems for business clients. The combined company is expected to trade on the Nasdaq once the deal is completed in late 2024. Transaction Overview...
At the SPAC of Dawn The market shifted this week on the see-saw of the US election prospects, but, beyond the policies at play, another impact the election could have on the SPAC market is the potential for a fair amount of people movement. Many of the biggest names in SPACland have been bundling donations...